NYSE:ELV 14 January 2026 - 4 June 2026

UnitedHealth Group shares climbed over 5% Thursday morning after Bank of America upgraded the stock to Buy and Morgan Stanley raised its price target. Wall Street is showing new support for the health insurer’s recovery bet. Investors are weighing if UnitedHealth’s first-quarter bounce really means medical costs are settling down, or if it was just a blip from lighter flu season and bad weather. Managed-care stocks have traded on medical-cost “utilization”—how often people go to the doctor—after a run of bigger claims. BofA’s Kevin Fischbeck said new data “make it more difficult to believe” Q1 was all about flu and storms, according to TipRanks.

UnitedHealth Group shares climbed Tuesday, last changing hands at $396.45, up $12.01—roughly a 3.1% jump. The session saw some volatility: the stock kicked off at $383.68, dipped to $382.06, before momentum took over and bulls drove it up to $397.33 toward the close. It matters now because investors have shifted focus: instead of simply questioning whether UnitedHealth can contain last year’s regulatory and cost setbacks, they’re beginning to factor in a recovery that looks less tangled. On Tuesday, senior executives will discuss strategy, financial performance, and market outlook at the BofA Securities Health Care Conference, as detailed in an 8-K filing. That gives Wall Street a fresh progress report following the April earnings reset.

New York, Jan 13, 2026, 19:13 EST — After-hours Shares of UnitedHealth Group Incorporated dropped nearly 2% Tuesday, deepening a retreat sparked by a U.S. Senate report scrutinizing how the insurer logs diagnoses in Medicare Advantage. Humana, Elevance Health, and Cigna also saw declines.